Search Results for: Pharma: Clinical Roundup
-
Clinic Roundup
Enobia Pharma Inc., of Montreal, started a Phase II trial to test two different doses of ENB-0040, a bone-targeted enzyme replacement therapy, in hypophosphatasia...Those data were published in the November 2009 issue of the Journal of Urology, and the company has started two clinical studies, each to enroll 1,000 subjects, to evaluate its bladder cancer assayBioWorld Today | Wednesday, November 4, 2009 -
Allos Expands Offering, Adds $100M for Folotyn Launch Prep
AspenBio Pharma Inc., of Castle Rock, Colo., priced a public offering of 4.5 million shares of common stock at $1.70 each...Funds are expected to support certain clinical studies of CPP-109 in cocaine addiction, to complete one or more nonclinical studies related to recently in-licensed compounds and for general corporate purposesBy Jennifer Boggs | BioWorld Today | Thursday, October 8, 2009 -
Clinic Roundup
Nektar Therapeutics, of San Carlos, Calif., presented clinical study data demonstrating that the oral tablet formulation of NKTR-118 has favorable systemic bioavailability and a low risk for mediating significant drug-drug interactionsBioWorld Today | Tuesday, September 15, 2009 -
Adamas Snags Navy Flu Drug Contract, Raises $40M Series D
Adamas is conducting a Phase II trial of its TCAD flu therapy, which is designed to inhibit viral replication at multiple points in the virus proliferation pathway, in the Southern Hemisphere, where the H1N1 pandemic is active, and is preparing to initiate a clinical study of the therapy in North America during this upcoming flu season, Went said...Participants include Purdue Pharma LP, HBM BioCapital LP, the Pritzker/Vlock family and other substantial private life science investors. #kicker123By Donna Young | BioWorld Today | Wednesday, August 19, 2009 -
Presidio Gets $27M B-Extension for Preclinical HCV Programs
raised $27 million in a Series B extension to drive clinical trials of PPI-461, a preclinical small-molecule NS5A inhibitor for hepatitis C...At the annual meeting of the European Association for the Study of the Liver (EASL) in April, data from the first-ever clinical study to combine two direct antivirals garnered plenty of attentionBy Trista Morrison | BioWorld Today | Monday, July 13, 2009 -
Clinic Roundup
Amarillo Biosciences Inc., of Amarillo, Tex., has selected Accelovance Inc., a clinical research organization based in Rockville, Md., to conduct a human clinical study of the company's oral interferon product during the upcoming 2009-2010 influenza season in the U.S. The new Phase II trial will be a follow-up to the ongoing study at the University of Western Australia, which is already under wayBioWorld Today | Thursday, May 21, 2009 -
Clinic Roundup
Pulmatrix said it expects to advance PUR003 into multiple clinical studies to demonstrate its use in the treatment, prevention and control of infectious and progressive respiratory diseases this year, including influenza...Tranzyme Pharma Inc., of Research Triangle Park, N.C., said that it plans to present its successful Phase II study results of ghrelin agonist TZP-101 for the management of postoperative ileus (POI) at the upcoming 2009 Annual Meeting of the American Society of Colon and RectalBioWorld Today | Tuesday, May 5, 2009 -
INFORM-1 Data Pave the Way for Direct Antiviral Combos in HCV
Principal investigator Ed Gane of Auckland Clinical Studies said the INFORM-1 trial was "based on the rationale from the HIV treatment paradigmBy Trista Morrison | BioWorld Today | Tuesday, April 28, 2009 -
Ahead of Solzira Resubmission, XenoPort Adds $40M in Offering
But a subgroup analysis indicated that XP19986 monotherapy was effective in reducing heartburn in patients with GERD who previously had responded to proton-pump inhibitors and XenoPort plans to conduct a further study in the next year. (See BioWorld Today, Dec. 3, 2008.) The company also expects to initiate a clinical study of XP19986 in acute back spasms, Cossmon said...The London-based pharma firm originally filed the NDA in September, based on data from three Phase III studies showing that theBy Jennifer Boggs | BioWorld Today | Wednesday, December 31, 2008 -
Clinic Roundup
Enobia Pharma Inc., of Montreal, said it dosed the first infant patient in its clinical program of ENB-0040 in hypophosphatasia, a rare genetic bone disorder...Marshall Edwards Inc., of New Canaan, Conn., said it has filed an investigational new drug application with the FDA to undertake clinical studies with triphendiol as a chemosensitizing agent in combination with gemcitabineBioWorld Today | Tuesday, December 2, 2008 -
Clinic Roundup
DOR BioPharma Inc., of Ewing, N.J., said it has reached agreement with the FDA on the key clinical study design components of a confirmatory Phase III study evaluating OrBec for the treatment of acute gastrointestinal graft-versus-host disease...Other data from preclinical and clinical studies demonstrated that HIF-PHI compounds are orally active, which also sets them apart from ESAs, which must be administered by injectionBioWorld Today | Tuesday, November 11, 2008 -
Clinic Roundup
The results demonstrated that exposure to orally administered picoplatin was linear at doses below 200 mg, and that maximum exposure to orally administered picoplatin was achieved at doses of 200 mg or greater indicating sufficient bioavailability to support further clinical studies...The final clinical study report is expected in early 2009BioWorld Today | Friday, November 7, 2008 -
Clinic Roundup
GL1001, the first clinical-stage inhibitor of the ACE2 enzyme, was administered previously in a Phase I single ascending-dose clinical study completed in the UK, where it was well tolerated and exhibited favorable pharmacokinetics consistent with once-daily dosingBioWorld Today | Thursday, October 2, 2008 -
Clinic Roundup
Align Pharmaceuticals LLC, a wholly owned subsidiary of Cyclacel Pharmaceuticals Inc., of Berkeley Heights, N.J., announced results of a double-blinded, randomized, vehicle-controlled clinical study showing that Xclair cream (formerly MAS065D) is safe and effective in the treatment and prevention of radiation dermatitis...SymBio Pharmaceuticals Ltd., of Tokyo, said it has completed target enrollment of patients with mantle cell lymphoma for an ongoing Phase II clinical study of bendamustineBioWorld Today | Tuesday, July 8, 2008 -
Congress Hears Opposing Views in Follow-on Biologics Debate
As it is not possible to predict the clinical consequences of such differences, it is necessary to conduct clinical studies in order to demonstrate similarity to the innovator biologic and an absence of clinically meaningful difference," the Thousand Oaks, Calif.-based biotech contendedBy Donna Young | BioWorld Today | Monday, June 23, 2008 -
Clinic Roundup
Inovio Biomedical Corp., of San Diego, said a clinical study of an experimental DNA-based prostate cancer vaccine has reaffirmed that, post-treatment, the therapy is safe and well tolerated...Tranzyme Pharma, of Research Triangle Park, N.C., reported positive results from a Phase IIa study of first-in-class ghrelin agonist TZP-101 in diabetesBioWorld Today | Friday, June 6, 2008 -
Clinic Roundup
Starpharma Holdings Ltd., of Melbourne, Australia, showed positive results of its clinical study demonstrating that 3 percent SPL7013 Gel (VivaGel) was safe and well tolerated in sexually abstinent women when administered vaginally, twice daily for 14 days...Those findings support current and future clinical studies to assess the safety and efficacy of VivaGel for genital herpes and HIV in sexually active womenBioWorld Today | Tuesday, May 13, 2008 -
Good Data on Riquent in Hand, La Jolla Seeks $30M Offering
Proceeds will be used to repay the remaining balance of an existing working capital loan, fund clinical studies and for general corporate purposes...NovaDel Pharma Inc., of Flemington, N.J., said it has entered into definitive agreements for the private placement for an aggregate of up to $4 million in gross proceeds in the form of secured convertible promissory notes with an interest rate of 10 percent and warrants to purchase shares of the company's common stockBy Staff Reports | BioWorld Today | Thursday, May 8, 2008 -
Clinic Roundup
The trial met its objectives of evaluating the safety profile and pharmacokinetic of CF102 single doses, and of determining a dose range for future clinical studies...N30 Pharma, of Boulder, Colo., said it successfully completed Phase I study of N30-201 in patients with mild to moderate asthma, as well as healthy volunteersBioWorld Today | Tuesday, May 6, 2008 -
AACR Roundup
Adventrx Pharmaceuticals Inc., of San Diego, said its registrational bioequivalence clinical study of ANX-530 (vinorelbine emulsion) met its primary endpoint and a new drug application will be submitted by the end of the year...In a separate presentation, Medivation reported clinical results of its Alzheimer's drug Dimebon, showing that it led to significant improvement in patients' ability to perform daily tasks over a one-year period compared to placeboBioWorld Today | Wednesday, April 16, 2008
Category
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.